|
It was reported the physician was implanting a 30mm gore® cardioform septal occluder to close a long tunnel, aneurysmal patent foramen ovale.Both disc did not oppose the septum well, so the device was repositioned twice.On the third attempt, the left disc prolapsed into the tunnel.The device was deployed again, and a shunt was still present.The device was removed in favor of trying a larger device.At this point, the patient became symptomatic and a pericardial effusion was noted in the superior portion of the left atrium.The patient was treated with a pericardiocentesis.The patient was sent for surgical repair of the effusion and closure of the pfo.The patient was doing well following the surgery.
|
|
The gore® cardioform septal occluder instructions for use state in the section ¿potential device ¿ or procedure-related adverse events¿
adverse events associated with the use of the occluder may include, but are not limited to:
¿ significant pleural or pericardial effusion requiring drainage.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|